[go: up one dir, main page]

ES2136103T3 - Procedimiento para la preparacion de derivados de estaurosporina. - Google Patents

Procedimiento para la preparacion de derivados de estaurosporina.

Info

Publication number
ES2136103T3
ES2136103T3 ES93109935T ES93109935T ES2136103T3 ES 2136103 T3 ES2136103 T3 ES 2136103T3 ES 93109935 T ES93109935 T ES 93109935T ES 93109935 T ES93109935 T ES 93109935T ES 2136103 T3 ES2136103 T3 ES 2136103T3
Authority
ES
Spain
Prior art keywords
formula
staurosporin
represented
derivative
procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93109935T
Other languages
English (en)
Inventor
Chikara Murakata
Toshimitsu Takiguchi
Shigeo Katsumata
Akira Mihara
Keiichi Takahashi
Hiromitsu Saito
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KH Neochem Co Ltd
Original Assignee
Kyowa Hakko Kogyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP04162813A external-priority patent/JP3112343B2/ja
Application filed by Kyowa Hakko Kogyo Co Ltd filed Critical Kyowa Hakko Kogyo Co Ltd
Application granted granted Critical
Publication of ES2136103T3 publication Critical patent/ES2136103T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
    • C07H9/06—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing nitrogen as ring hetero atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE PRESENTA UN PROCESO PARA PRODUCIR UN DERIVADO DE LA ESTAUROSPORINA REPRESENTADO POR LA FORMULA (I) EN LA QUE Q REPRESENTA HIDROGENO O -X-(CH2)M-Y-(CH2)N-Z O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL COMPUESTO, QUE COMPRENDE LA OXIDACION DE UN COMPUESTO REPRESENTADO POR LA FORMULA II EN LA QUE Q TIENE EL MISMO SIGNIFICADO QUE EL DEFINIDO PREVIAMENTE, CON DIMETILSULFOXIDO (DMSO) Y UNA SOLUCION ALCALINA ACUOSA. TAMBIEN SE PRESENTA UN NUEVO DERIVADO DE LA ESTAUROSPORINA REPRESENTADO POR LA FORMULA I EN LA QUE Q ES -X_(CH2)M-Y-(CH2)4Z. EL DERIVADO DE LA ESTAUROSPORINA POSEE ACTIVIDADES INHIBIDORAS DE LA QUINASA C SELECTIVA DE LA PROTEINA Y ACTIVIDADES INHIBIDORAS DEL CRECIMIENTO CELULAR, Y ACTIVIDAD PARA EL INCREMENTO DE LAS PLAQUETAS.
ES93109935T 1992-06-22 1993-06-22 Procedimiento para la preparacion de derivados de estaurosporina. Expired - Lifetime ES2136103T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP04162813A JP3112343B2 (ja) 1992-06-22 1992-06-22 Ｕｃｎ−０１の製造法
JP16281492 1992-06-22

Publications (1)

Publication Number Publication Date
ES2136103T3 true ES2136103T3 (es) 1999-11-16

Family

ID=26488474

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93109935T Expired - Lifetime ES2136103T3 (es) 1992-06-22 1993-06-22 Procedimiento para la preparacion de derivados de estaurosporina.

Country Status (4)

Country Link
US (1) US5344926A (es)
EP (1) EP0575955B1 (es)
DE (1) DE69326388T2 (es)
ES (1) ES2136103T3 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2155379A1 (es) * 1999-04-05 2001-05-01 Univ Cantabria Procedimiento para producir plaquetas humanas a partir de celulas en cultivo.

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5756494A (en) * 1992-07-24 1998-05-26 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
DE69331228D1 (en) * 1992-09-21 2002-01-10 Kyowa Hakko Kogyo Kk Heilmittel für thrombozytopenia
US6306421B1 (en) 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6663881B2 (en) * 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
WO1994020106A1 (fr) * 1993-03-03 1994-09-15 Kyowa Hakko Kogyo Co., Ltd. Renforceur de sensibilite pour agent antineoplasique
PH30300A (en) * 1993-05-07 1997-01-20 Ciba Geigy Ag Polycyclic compounds and processes for the preparation thereof
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
US5599808A (en) * 1994-02-18 1997-02-04 Cephalon, Inc. Aqueous indolocarbazole solutions
US5604219A (en) * 1994-03-18 1997-02-18 Kyowa Hakko Kogyo Co., Ltd. Indolocarbazole derivatives that stimulate platelet production
CA2170888A1 (en) * 1994-07-04 1996-01-18 Masahiko Kinugawa Process for producing indolocarbazole derivative
US7611533B2 (en) 1995-06-07 2009-11-03 Cook Incorporated Coated implantable medical device
US6875865B1 (en) 1996-06-03 2005-04-05 Cephalon, Inc. Selected derivatives of K-252a
UA67725C2 (en) 1996-06-03 2004-07-15 Cephalon Inc K-252a derivatives and a method for improvement of functioning and cell survival enhancement
EP0912184B1 (en) 1996-06-25 2002-09-25 Cephalon, Inc. Use of k-252a derivative for the treatment of peripheral or central nerve disorders, and cytokine overproduction
US6127401A (en) * 1998-06-05 2000-10-03 Cephalon, Inc. Bridged indenopyrrolocarbazoles
US6013646A (en) 1998-07-02 2000-01-11 Bayer Corporation Indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer
JP2000186092A (ja) * 1998-12-22 2000-07-04 Kyowa Hakko Kogyo Co Ltd Ｕｃｎ−０１の製造法
US6284783B1 (en) 1999-06-09 2001-09-04 The Uab Research Foundation Use of bisindolylmaleimide compounds to induce Fas-mediated apoptosis
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
EP1441737B1 (en) 2001-10-30 2006-08-09 Novartis AG Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
DE60327347D1 (de) 2002-09-30 2009-06-04 Univ Auburn Verfahren und isolierung zur selbstzusammenlagerung kleiner proteinpartikel aus blut und anderen biologischen materialien
ATE328112T1 (de) * 2003-03-07 2006-06-15 Ist Naz Stud Cura Dei Tumori Anaplastisches lymphoma kinase testverfahren, reagenzien und kompositionen davon
WO2004094645A1 (en) * 2003-04-22 2004-11-04 Lonza Ag Process for the recovery of staurosporine from a fermentation broth
BRPI0413439A (pt) 2003-08-08 2006-10-17 Novartis Ag combinações compreendendo estaurosporinas
JO2897B1 (en) 2004-11-05 2015-09-15 نوفارتيس ايه جي Organic compounds
KR102272233B1 (ko) 2012-12-12 2021-07-01 프로메가 코포레이션 생체활성 제제의 세포 표적 포획을 위한 조성물 및 방법
US10168323B2 (en) 2013-03-15 2019-01-01 Promega Corporation Compositions and methods for capture of cellular targets of bioactive agents
TWI538914B (zh) * 2014-10-03 2016-06-21 國立交通大學 蛋白質激酶之選擇性抑制劑、其醫藥組成物及其用途
IT201900004729A1 (it) 2019-03-29 2020-09-29 Procos Spa Processo per la preparazione di midostaurina ad elevato grado di purezza

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62220196A (ja) * 1986-03-20 1987-09-28 Kyowa Hakko Kogyo Co Ltd 新規物質ｕｃｎ―０１
DE3752123T2 (de) * 1987-03-09 1998-05-14 Kyowa Hakko Kogyo Kk Derivate des physiologisch aktiven mittels k-252
JPH07113027B2 (ja) * 1987-12-24 1995-12-06 協和醗酵工業株式会社 Ｋ−２５２誘導体
WO1989007105A1 (fr) * 1988-02-04 1989-08-10 Kyowa Hakko Kogyo Co., Ltd. Derives de staurosporine
US5015578A (en) * 1989-03-23 1991-05-14 Bristol-Myers Squibb Company BMY-41950 antitumor antibiotic
WO1991009034A1 (en) * 1989-12-14 1991-06-27 Schering Corporation Indolocarbazoles from saccharothrix aerocolonigenes subsp. copiosa subsp. nov. scc 1951 atcc 53856
US4973552A (en) * 1990-02-20 1990-11-27 Bristol-Meyers Squibb Company Staurosporine fermentation process
WO1992018507A1 (en) * 1991-04-11 1992-10-29 Schering Corporation Anti-tumor and anti-psoriatic agents

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2155379A1 (es) * 1999-04-05 2001-05-01 Univ Cantabria Procedimiento para producir plaquetas humanas a partir de celulas en cultivo.

Also Published As

Publication number Publication date
EP0575955B1 (en) 1999-09-15
EP0575955A1 (en) 1993-12-29
DE69326388D1 (de) 1999-10-21
DE69326388T2 (de) 1999-12-30
US5344926A (en) 1994-09-06

Similar Documents

Publication Publication Date Title
ES2136103T3 (es) Procedimiento para la preparacion de derivados de estaurosporina.
ATE85057T1 (de) Optisch aktive pyridobenzoxazinderivate.
ATE20748T1 (de) Guaninderivate.
CU22305A3 (es) Procedimiento para la preparacion de un derivado de aminoacidos
YU49312B (sh) Kristalni hidratni derivati 3,4,4-trisupstituisanih - peperidinil-n-alkilkarboksilata, njihovi intermedijari i postupak za dobijanje
ES2076147T3 (es) Nuevos derivados de amina ciclicos, medicamento que contiene estos compuestos y procedimiento para su preparacion.
ES472742A1 (es) Procedimiento para la obtencion de derivados de alqueno
FI862757A0 (fi) Pyridonkarbonsyraderivat och foerfarande foer framstaellning av dessa.
UA35574C2 (uk) Похідні заміщеної гетероциклом фенілциклогексанкарбонової кислоти, суміші їх ізомерів або окремі ізомери та їх солі
NO940523D0 (no) Nye pyrazin-derivater
ES513420A0 (es) "procedimiento para preparar derivados de 2-oxoazetidina".
ES8500247A1 (es) Un procedimiento para la preparacion de un isomero optico en su forma (-) de un derivado de triazina.
CO4970779A1 (es) Derivados del acido aminoetilfenoxiacetico y agentes para reducir el dolor y promover la eliminacion de calculos en urolitiasis
ES2061794T3 (es) Nuevos derivados de benzazepina.
SE8101311L (sv) Heterocykliska foreningar
ES2020925B3 (es) Nuevas sales cristalinas de ariloxipropanolaminas, procedimiento para su preparacion y utilizacion de las mismas.
DE69517806D1 (de) Stabile wässrige folinatlösung
ES2037758T3 (es) Un metodo de uso de un derivado quinolincarboxilico y su procedimiento de preparacion.
LV10098A (lv) Metilpiperazinazepina atvasinajumi to iegusana un lietosana
IT1201963B (it) Derivati delle rifamicine e procedimento per la loro preparazione
ATE259800T1 (de) Substituierte 5-(2,2difluor-1,3-benzodioxol-5-yl) cyclopentenopyridinderivate
ES8706649A1 (es) Un procedimiento para preparar derivados de 6-amino-3-hidrazinopiridazina
FI934468A0 (fi) Bensenborsyraderivat, foerfarande foer deras framstaellning och deras anvaendning som sytesmellanprodukter
ES8300747A1 (es) Procedimiento para la preparacion de derivados de acido in- dolacetico
SU1573800A1 (ru) Производные о-аминобензойной кислоты, обладающие фунгицидными свойствами

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 575955

Country of ref document: ES